ENT Updates

Clinical Research

Nasal nitric oxide and its metabolites as potential biomarkers for the diagnosis and follow-up of allergic rhinitis

Downloads

https://doi.org/10.2399/jmu.2017003001
Özergin Coşkun, Z., Arslan, S., Değer, O., & İmamoğlu, M. (2017). Nasal nitric oxide and its metabolites as potential biomarkers for the diagnosis and follow-up of allergic rhinitis. ENT Updates, 7(3). https://doi.org/10.2399/jmu.2017003001
Volume 7 Issue 3 (2017)
Copyright (c) 2017 Zerrin Özergin Coşkun, Selçuk Arslan, Orhan Değer, Mehmet İmamoğlu
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors

  • Zerrin Özergin Coşkun
    Department of Otorhinolaryngology - Head and Neck Surgery, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey
  • Selçuk Arslan Department of Otorhinolaryngology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
  • Orhan Değer Department of Medical Biochemistry, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
  • Mehmet İmamoğlu Department of Otorhinolaryngology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey

Objective: This study was conducted to investigate nasal nitric oxide (nNO) and its metabolites nasal nitrite-nitrate (nNOx) in patients with allergic rhinitis (AR), the effects of two different drugs (oral antihistamine and intranasal steroid) on nNOx and the presence of a correlation between nNOx and clinical parameters.

Methods: Sixty patients with active symptoms of perennial AR and 25 healthy adults as a control group were enrolled. The patients were randomized into two groups. Half of the patients received fexofenadine 1x120 mg/day orally, and the other half received triamcinolone acetonide 1x2 puff/day intranasally for one month. The amount of nNOx in nasal lavage fluid was measured by using a commercially available kit and the photometric endpoint determination method.

Results: Pre-treatment levels of NOx in the nasal lavage fluids (1.92± 1.20 mg/l) of patients with AR were found to be significantly higher when compared with nasal lavage fluid NOx levels of healthy adults (1.38±0.78 mg/l) (p=0.04). The post-treatment nNOx level (1.52±0.85 mg/l) was significantly lower when compared with the pre-treatment value (p=0.028).

Conclusion: Nasal nitric oxide metabolites were shown to be good biomarkers for AR, and that oral fexofenadine significantly decreased nNOx levels.

Keywords:

Allergic rhinitis nitric oxide nitrite nitrate nasal lavage fexofenadine triamcinolone acetonide nasal steroid antihistaminic